Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.

Trial Profile

Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use

Most Recent Events

  • 01 Aug 2019 Results assessing the efficacy and safety of istradefylline in improving gait disorders with freezing of gait questionnaire in patients with Parkinson's disease published in the Expert Opinion on Pharmacotherapy
  • 22 Aug 2018 Status changed from active, no longer recruiting to completed.
  • 13 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top